株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

生物製剤の世界市場 - 動向と予測:2018年〜2028年

Biologics Market Trends and Forecasts 2018-2028

発行 Visiongain Ltd 商品コード 235218
出版日 ページ情報 英文 303 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.96円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
生物製剤の世界市場 - 動向と予測:2018年〜2028年 Biologics Market Trends and Forecasts 2018-2028
出版日: 2018年11月14日 ページ情報: 英文 303 Pages
概要

世界の生物製剤市場は、2023年には2,500億米ドルに達すると予測されています。市場は、2018年〜2023年のCAGR (複合年間成長率) で、4.8%の成長が予測されています。

当レポートでは、世界の生物製剤市場について調査分析し、市場概要、二次市場の分析と予測、主要国の市場予測、定性分析、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 市場力学

  • 促進要因
  • 抑制要因
  • 機会
  • 動向

第3章 生物製剤市場と主要コンセプトのイントロダクション

  • 生物製剤:大規模かつ複雑な製品
  • 生物製剤開発の沿革
  • 世界の医薬品市場で生物製剤が最も収益性が高い理由
  • バイオシミラーとは
  • 境界症例
  • ワクチン市場

第4章 世界の生物製剤市場

  • 世界の生物製剤市場
  • 市場成長促進要因
  • バイオシミラー:機会と脅威
  • 市場成長抑制要因
  • 生物製剤市場:二次市場の予測

第5章 タンパク質製剤二次市場

  • 大規模かつ最も多様な二次市場
  • タンパク質は19世紀から医療に利用
  • タンパク質製剤二次市場の予測
  • インスリン二次市場
  • バイオシミラーインスリン
  • その他の組み換えホルモン:エリスロポエチン、G-CSF、ヒト成長ホルモン
  • 血漿・組み換え凝固因子
  • インターフェロン
  • 酵素置換・その他のタンパク質療法二次市場

第6章 モノクローナル抗体 (mAb) 二次市場

  • モノクローナル抗体二次市場:科学的・歴史的背景
  • 自己免疫モノクローナル抗体
  • がんモノクローナル抗体
  • モノクローナル抗体二次市場の予測

第7章 融合タンパク質製剤二次市場

  • 科学的・歴史的背景
  • 融合タンパク質製剤 (FP) の差別化
  • Enbrel
  • Eylea
  • Orencia
  • Nplate
  • Eloctate
  • Nulojix
  • Arcalyst (Regeneron Pharmaceuticals)
  • 融合タンパク質製剤パイプライン
  • 融合タンパク質製剤二次市場

第8章 再生医療二次市場

  • 再生医療市場の内訳
  • 再生医療二次市場の予測
  • 幹細胞治療二次市場
  • 組織工学治療二次市場
  • 遺伝子治療二次市場

第9章 主要国の生物製剤市場

  • 地域別の生物製剤市場の予測
  • 米国
  • EU5ヶ国
  • 日本
  • BRIC諸国

第10章 生物製剤市場・産業の定性分析

  • SWOT分析
  • STEP分析

第11章 企業プロファイル

  • AbbVie Inc.
  • Amgen
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

第12章 結論

図表

List of Tables

  • Table 3.1: First Approvals for Recombinant Protein Therapies, 1982-1993
  • Table 4.1: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.2: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 4.3: Patent Status of Selected Leading Biologics
  • Table 4.4: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
  • Table 4.5: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
  • Table 5.1: First Approvals for Recombinant Protein Therapies,1982-1993
  • Table 5.2: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.3: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 5.4: Diabetes Prevalence in Leading National Markets, 2017
  • Table 5.5: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.6: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 5.7: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.8: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
  • Table 5.9: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.10: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 5.11: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2018-2023
  • Table 5.12: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
  • Table 5.13: Selected Insulin Biosimilars which have been Approved and Launched
  • Table 5.14: Selected EPO Biosimilars Approved in India
  • Table 5.15: European Biosimilar Approvals: G-CSF
  • Table 5.16: Selected Filgrastim Biosimilars Approved Worldwide, 2016
  • Table 5.17: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.18: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
  • Table 5.19: Selected Coagulating Factors Significant in Segment
  • Table 5.20: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.21: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
  • Table 5.22: Selected Approved Branded Interferon Therapies
  • Table 5.23: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.24: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), to 2028
  • Table 5.25: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.26: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2023-2028
  • Table 5.27: Selected Interferon Alfa Biosimilars Approved Worldwide, 2016-2017
  • Table 5.28: Selected Interferon Beta Biosimilars Approved Worldwide, 2016-2017
  • Table 5.29: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.30: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 5.31: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 5.32: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2023-2028
  • Table 6.1: Regions of an Antibody
  • Table 6.2: Natural Antibody Mechanisms of Action
  • Table 6.3: Selected Biosimilar Adalimumab Candidates
  • Table 6.4: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 6.5: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 6.6: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 6.7: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
  • Table 6.8: Stelara Revenue 2015-2017: Revenues ($bn), AGR (%)
  • Table 6.9: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 6.10: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 6.11: Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2016-2017
  • Table 6.12: Selected Ongoing Lebrikizumab Clinical Trials
  • Table 6.13: Selected Ongoing Anifrolumab Clinical Trials
  • Table 6.14: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2018-2023
  • Table 6.15: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
  • Table 6.16: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2018-2023
  • Table 6.17: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
  • Table 6.18: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 6.19: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 6.20: FDA-Approved Indications for Cyramza
  • Table 6.21: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 6.22: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 7.1: Amgen's US Patents and Expiry Dates for Enbrel
  • Table 7.2: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 7.3: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2023-2028
  • Table 7.4: Eylea Revenue Breakdown 2016-2017: Regeneron and Bayer
  • Table 7.5: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 7.6: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 7.7: Bristol-Myers Squibb's pipeline developments for Orencia
  • Table 7.8: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 7.9: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.1: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.2: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.3: Potency and Source of Stem Cells
  • Table 8.4: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.5: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.6: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2023
  • Table 8.7: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2023-2028
  • Table 8.8: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.9: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.10: Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.11: Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.12: Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.13: Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 8.14: IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.15: IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2028
  • Table 9.1: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
  • Table 9.2: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2028
  • Table 9.3: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2018-2023
  • Table 9.4: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2023-2028
  • Table 9.5: European Biosimilar Approvals, 2006-2017
  • Table 9.6: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2018-2023
  • Table 9.7: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2023-2028
  • Table 9.8: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2018-2023
  • Table 9.9: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2023-2028
  • Table 9.10: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2018-2023
  • Table 9.11: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2023-2028
  • Table 11.1: AbbVie, Inc.: Profile
  • Table 11.2: AbbVie, Inc.: Key Developments
  • Table 11.3: Amgen: Profile
  • Table 11.4: Amgen: Key Developments
  • Table 11.5: AstraZeneca PLC: Profile
  • Table 11.6: AstraZeneca PLC: Key Developments
  • Table 11.7: Bayer AG: Profile
  • Table 11.8: Eli Lilly: Profile
  • Table 11.9: Eli Lilly: Key Developments
  • Table 11.10: Roche: Profile
  • Table 11.11: Roche: Key Developments
  • Table 11.12: GSK: Profile
  • Table 11.13: Johnson & Johnson: Profile
  • Table 11.14: Johnson & Johnson: Profile
  • Table 11.15: Merck & Co., Inc.: Profile
  • Table 11.16: Merck & Co., Inc.: Key Developments
  • Table 11.17: Novartis: Profile
  • Table 11.18: Novartis: Key Developments
  • Table 11.19: Pfizer: Profile
  • Table 11.20: Pfizer: Key Developments
  • Table 11.21: Sanofi: Profile
  • Table 11.22: Sanofi: Key Developments

List of Figures

  • Figure 1.1: Forecasted Submarkets of the Biologics Market
  • Figure 4.1: Global Biologics Market Forecast: Revenues ($bn), 2018 - 2028
  • Figure 4.2: Submarkets within the Biologics Market Forecast: Revenues ($bn),2017-2028
  • Figure 5.1: Protein Therapeutics Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.2: Diabetes Prevalence in Leading National Markets, 2017
  • Figure 5.3: Insulin Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.4: Lantus Revenue Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.5: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.6: Humalog Revenue Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.7: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.8: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.9: Avonex Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.10: Rebif Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 5.11: Interferon Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 5.12: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), 2018 - 2028
  • Figure 6.1: Humira Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 6.2: Remicade Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 6.3: Stelara Revenue 2015-2017, Revenue ($bn)
  • Figure 6.4: Tysabri Revenue Forecast: Revenue ($m), 2018 - 2028
  • Figure 6.5: Herceptin Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 6.6: Kadcyla Revenue Forecast: Revenue ($m), 2018 -2028
  • Figure 6.7: Perjeta Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 6.8: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), 2018 - 2028
  • Figure 7.1: Enbrel Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 7.2: Eylea Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 7.3: Fusion Proteins Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.1: Regenerative Medicines Market Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.2: Osteocel Plus Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.3: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), 2018 - 2028
  • Figure 8.4: Stem Cell Therapies Market Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.5: Apligraf Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.6: Dermagraft Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 8.7: IMLYGIC Revenue Forecast: Revenue ($bn), 2018 - 2028
  • Figure 9.1: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2017
  • Figure 9.2: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2028
  • Figure 9.3: Regional Forecasts for Global Biologics Market: Revenues ($bn),to 2028
  • Figure 9.4: US Biologics Market: Revenues ($bn), 2018 - 2028
  • Figure 9.5: EU5 Market Breakdown: Market Share (%), 2017
  • Figure 9.6: EU5 Biologics Market: Revenues ($bn), 2018 - 2028
  • Figure 9.7: Japanese Biologics Market: Revenues ($bn), 2018 - 2028
  • Figure 9.8: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2017
  • Figure 9.9: BRIC Biologics Market: Revenues ($bn), 2018 - 2028
  • Figure 9.10: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2028
  • Figure 10.1: SWOT Analysis of Biologics Market and Industry
  • Figure 10.2: STEP Analysis of Biologics Market and Industry
  • Figure 12.1: Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2018 - 2028

COMPANIES LISTED:

  • 3SBio
  • AbbVie
  • Ablynx
  • Acceleron Pharma
  • Accord Healthcare
  • Aché
  • Actavis
  • Adaptive Biotechnologies Corporation
  • Advanced BioHealing
  • Advantagene
  • Advaxis, Inc.
  • Afferent Pharmaceuticals
  • Alder Biopharmaceuticals
  • Alector
  • Allergan
  • Alteogen
  • Amega Biotech
  • Amgen
  • AM-Pharma B.V.
  • Anacor Pharmaceuticals, Inc.
  • AnGes
  • Anthera Pharmaceuticals
  • Apceth
  • Apeiron Biologics
  • Apotex
  • Argenx
  • ARMO BioSciences, Inc.
  • Aryogen
  • Aspen Global Incorporated
  • Astellas Pharma
  • AstraZeneca
  • AurKa Pharma, Inc.
  • Aventis
  • Avita Medical
  • Bamboo Therapeutics, Inc.
  • Banner Alzheimer's Institute
  • Basilea Pharmaceutica Ltd.
  • Baxalta
  • Bayer
  • Beijing Four Rings
  • Beijing SL Pharmaceutical
  • Benda Pharmaceuticals
  • Biocad
  • BioCardia
  • Biocon
  • Biodel
  • Biogen
  • Bionovis
  • Biopartners
  • BioPharma
  • Biosidus
  • Biotest
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb (BMS)
  • Cambridge Antibody Technology
  • cCAM Biotherapeutics
  • CCL Pharmaceuticals
  • Celgene Corporation
  • Celltrion
  • CEL-SCI
  • Centocor Ortho Biotech
  • Children's Oncology Group
  • CHMP
  • Chugai
  • CinnaGen
  • ClinImmune Labs
  • CSL Behring
  • CT Arzneimittel
  • CureVac AG
  • Cystic Fibrosis Foundation Therapeutics Inc
  • CytomX Therapeutics
  • Daiichi Sankyo Company, Limited
  • Dako
  • Dendreon
  • Dezima Pharma B.V.
  • DNAtrix
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Dynavax Technologies Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • EMS
  • Epirus
  • Europharm
  • Evotec
  • FDA
  • FibroGen
  • FierceBiotech
  • Finox Biotech
  • Flatiron Health
  • Foundation Medicine, Inc.
  • Fuji Pharma
  • Galencia
  • Gan & Lee
  • GE Healthcare
  • Genentech
  • Gennova
  • GenSci
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Hangzhou Jiuyuan Gene Engineering Co.
  • Hanwha Chemical
  • Harpoon Therapeutics
  • Harrisvaccines Inc.
  • Heptares Therapeutics
  • Hexal
  • Hindustan Antibiotic
  • Histogenics
  • Hospira, Inc.
  • Human Genome Sciences
  • Humana Inc.
  • Hypermarcas
  • IBM Watson Health
  • ICU Medical Inc.
  • Ignyta, Inc.
  • Immatics Biotechnologies GmbH
  • Immune Design
  • Immunex Corporation
  • Immunocore Limited
  • Incyte Corporation
  • Innovare R&D
  • Intas Pharmaceuticals
  • IOmet Pharma
  • Ipsen
  • Isis Pharmaceuticals, Inc.
  • Janssen
  • JingYuan Bio
  • Johnson & Johnson
  • Kite Pharma
  • Kyowa Hakko Kirin
  • Laboratorios Delta
  • LG Life Sciences
  • LifeSouth Community Blood Centers
  • Lonza
  • Luye Pharma Group, Ltd.
  • M2Gen
  • MacroGenics, Inc.
  • Massachusetts General Hospital
  • Medice
  • MEDICE Arzneimittel Pütter
  • MedImmune
  • MEDIPOST
  • Medivation, Inc.
  • Medtronic
  • Merck & Co., Inc.
  • Merck KGaA
  • Merz Pharma
  • Mirati Therapeutics, Inc.
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Moderna Therapeutics
  • Mylan
  • NanoString Technologies, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Nippion Kayaku
  • Northwestern University
  • Novartis
  • Novo Nordisk
  • NuVasive
  • Oanda
  • Organogenes
  • OrLife Bio
  • Orthofix
  • Orygen
  • Peregrine Pharmaceuticals, Inc.
  • Pfizer
  • Pharmacyclics
  • Pharmicell
  • Pharmstandard
  • Plexxikon Inc.
  • Porbiomed
  • Portola Pharmaceuticals Inc.
  • Premier Inc.
  • Principia
  • Probiomed
  • Protein Sciences
  • Proteon Therapeutics
  • Qilu Pharmaceutical
  • Ranbaxy
  • Ratiopharm
  • Redvax GmbH
  • Regeneron Pharmaceuticals, Inc.
  • Regenerys
  • Reliance Life Sciences
  • Rentschler Biotechnologie.
  • Rigontec
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Schering-Plough
  • SciGen
  • Shandong Kexing Pharma
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Fosun
  • Shanghai Sunway Biotech
  • Shantha Biotechnics
  • Shenzhen SiBiono GeneTech
  • Shire
  • Sicor Biotech
  • Sigilon Therapeutics
  • Simcere Pharmaceutical Group
  • Smith and Nephew
  • Spark Therapeutics
  • Stada
  • Stemcentrx
  • Stragen Pharma
  • Stratatech Corporation
  • Swiss Re
  • Takeda Pharmaceutical Company Limited
  • TESARO, Inc.
  • TetraLogic Pharmaceuticals Corporation
  • Teva
  • Tianjin Hualida Biotechnology
  • TiGenix
  • Tonghua Dongbao
  • Trophos
  • Turnstone Biologics
  • UCB
  • União Química
  • UniQure
  • Valeant Pharmaceuticals
  • Vertex Pharmaceuticals
  • Viralytics Limited
  • Vital Therapies Inc.
  • Voyager Therapeutics
  • Wockhardt
  • Wyeth-Ayerst Laboratories
  • Xencor, Inc.
  • Xiamen Amoytop Biotech
  • XO1 Limited
  • Zenotech
  • ZS Pharma
  • Zuventus
  • Zydus Biovation
  • Zydus Cadila

Organizations Mentioned in the Report

  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Australia's Walter and Eliza Hall Institute
  • Boston Children's Hospital
  • Center for Disease Prevention and Control (CDC)
  • Central Drugs Standard Control Organisation
  • China Food and Drug Administration
  • Duke University School of Medicine
  • EMA (European Medicines Agency)
  • European Commission (EC)
  • European Federation of Pharmaceutical Industries and Associations
  • Harvard University
  • Human Stem Cells Institute
  • International Myeloma Foundation
  • Johns Hopkins
  • Musculoskeletal Transplant Foundation (MTF)
  • National Cancer Institute
  • New York Blood Center
  • NHS
  • NICE
  • Rice University
  • Saudi Food and Drug Authority
  • SSN Cardinal Glennon Children's Medical Center
  • Stanford University
  • The European Generic medicines Association (EGA)
  • The European Group for Blood and Marrow Transplantation (EBMT)
  • The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
  • The University of Manchester
  • The University of Texas
  • The University of Texas MD Anderson Cancer Center
  • Toronto University
  • Toronto University
  • UCSF (University of California, San Francisco)
  • United Therapeutics
  • University of California, Berkeley
  • University of Colorado Cord Blood Bank
  • University of Tokyo
  • US Center for Disease Prevention and Control (CDC)
  • US Food and Drug Administration
  • Walter and Eliza Hall Institute
  • World Bank
  • World Health Organization (WHO)
  • Yonsei University
目次
Product Code: PHA0341

Title:
BIOLOGICS MARKET TRENDS AND FORECASTS 2018-2028
Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 303-page report you will receive 166 charts- all unavailable elsewhere.

The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Biologics Market outlook from 2018-2028
  • Global Biologics Submarkets analysis and forecast from 2018-2028:
  • Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
  • Monoclonal antibodies (mAbs)
  • Fusion proteins
  • Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
  • Vaccines

Analysis and forecast from 2018-2028 for selected leading biologics in the market:

  • Lantus
  • NovoLog/NovoRapid
  • Humalog
  • Avonex
  • Rebif
  • Humira
  • Remicade
  • Tysabri
  • Herceptin
  • Kadcyla
  • Perjeta
  • Enbrel
  • Eylea
  • OsteoCel Plus
  • Trinity Evolution and Trinity Elite
  • Apligraf
  • Dermagraft
  • IMLYGIC

This report provides individual revenue forecasts from 2018-2028 for these national markets:

  • The US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • China
  • India
  • Russia
  • Brazil

Our study discusses the selected leading companies that are the major players in the biologics market:

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi S.A.

This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.

This report discusses the SWOT and STEP Analysis of the biologics market.

Visiongain's study is intended for anyone requiring commercial analyses for the biologics market. You find data, trends and predictions.

Buy our report today Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Biologics Overview
  • 1.2. Why you Should Read this Report
  • 1.3. How this Report Delivers
  • 1.4. Main Questions Answered by this Report
  • 1.5. Who is this Report for?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Market Dynamics

  • 2.1. Drivers
    • 2.1.1. Increasing Biologics Approvals
    • 2.1.2. Rise in the Prevalence of Chronic Diseases
  • 2.2. Restraints
    • 2.2.1. Complex in Nature
    • 2.2.2. High Cost
  • 2.3. Opportunities
    • 2.3.1. Strong Pipeline of biologics drugs
    • 2.3.2. Emerging technology
  • 2.4. Trends
    • 2.4.1. Growing strategic partnerships in China
    • 2.4.2. Outsourcing strategies

3. Introduction to the Biologics Market and Key Concepts

  • 3.1. Biologics: Large and Complex Products
  • 3.2. A Brief History of Biological Drug Development
  • 3.3. Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
  • 3.4. What are Biosimilars?
    • 3.4.1. Brief History of Biosimilars
    • 3.4.2. What are Interchangeable Biological Products and how do They Differ from Biosimilars?
    • 3.4.3. Why Many Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars
  • 3.5. Marginal Cases
  • 3.6. Vaccines Market

4. The Global Biologics Market 2018-2028

  • 4.1. The Global Biologics Market 2018-2028
  • 4.2. What Factors Will Drive Growth in the Biologics Market?
    • 4.2.1. Ageing Population and the Rise of Chronic Disease
    • 4.2.2. Biologics Constitute 19% of the Global Pharmaceutical Market-Further Launches Will Drive Market
  • 4.3. Biosimilars-Both an Opportunity and a Threat
  • 4.4. What Factors Will Restrain Growth in the Biologics Market?
    • 4.4.1. High Costs in the Face of Declining National Healthcare Budgets
    • 4.4.2. In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
    • 4.4.3. Over $100bn worth of Biologic Patents due to Expire by 2020
    • 4.4.4. Administration is Often not as Convenient
  • 4.5. Biologics Market: Submarket Forecasts 2018-2028

5. Protein Therapeutics Submarket 2018-2028

  • 5.1. Largest and Most Diverse Submarket
  • 5.2. Proteins have been used Medicinally since the 19th Century
    • 5.2.1. Recombinant DNA Technology-The Major Breakthrough in the use of Protein Drugs
  • 5.3. Protein Therapeutics Submarket Forecast 2018-2028
  • 5.4. Insulin Submarket 2018-2028
    • 5.4.1. The First Protein Therapeutic
    • 5.4.2. Around 430 Million People Expected to be Diagnosed with Diabetes by 2030
    • 5.4.3. Insulin Submarket Forecast 2018-2028
    • 5.4.4. Lantus: The Market Leading Drug by Far
      • 5.4.4.1. Lantus Revenue Forecast 2018-2028
    • 5.4.5. NovoLog/NovoRapid Revenue Forecast to 2028
    • 5.4.6. Humalog Revenue Forecast to 2028
    • 5.4.7. New Approvals and Pipeline
      • 5.4.7.1. Tresiba (Novo Nordisk)
      • 5.4.7.2. BIOD-123(Biodel)
  • 5.5. Biosimilar Insulin
    • 5.5.1. Approved Insulin Biosimilars
    • 5.5.2. Abasaglar/Basaglar/Insulin Glargine BS-The First Insulin Biosimilars to be Approved in Developed Markets. Delayed in the US
  • 5.6. Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone
    • 5.6.1. Erythropoietin
      • 5.6.1.1. First-Generation Therapies Launched in the 1980s
      • 5.6.1.2. Aranesp: Slowly Growing
      • 5.6.1.3. Epogen: Increases in Selling Price are No Longer Enough to Ward off Decline
      • 5.6.1.4. Procrit/Eprex: In Decline Since 2013
      • 5.6.1.5. NeoRecormon and Mircera (Roche) Provides Competition for Market Leader Amgen
      • 5.6.1.6. Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand
      • 5.6.1.7. The Challenge from Oral Therapies is Coming
      • 5.6.1.8. Treating Anaemia in Patients with CKD-The Leading Use of EPO Therapies
      • 5.6.1.9. Many Biosimilar Epoetins Approved Around the World
    • 5.6.2. G-CSF
      • 5.6.2.1. G-CSF: Discovered 1983. Recombinant Forms Available Since 1991
      • 5.6.2.2. Amgen Leads the Market
      • 5.6.2.3. Neupogen and Neulasta Revenues, and the Onpro Kit
      • 5.6.2.4. Teva Aiming to Challenge Amgen's Dominance
      • 5.6.2.5. Facing Much Biosimilar Competition Around the World
    • 5.6.3. Human Growth Hormone
      • 5.6.3.1. Human Growth Hormone: First Extracted in 1958
      • 5.6.3.2. Novo Nordisk Dominates Market
      • 5.6.3.3. Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
      • 5.6.3.4. Multiple Biosimilars Available-Omnitrope is Market Leader
      • 5.6.3.5. Biosimilar Growth Hormones in Asia
    • 5.6.4. Other Recombinant Hormones Submarket Forecast to 2028
  • 5.7. Plasma and Recombinant Coagulating Factors
    • 5.7.1. Types of Recombinant Factor
    • 5.7.2. Clotting Factor Deficiency Diseases
    • 5.7.3. Baxter/Baxalta: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products
      • 5.7.3.1. Baxter: New Product Launches Include Rixubis and Obizur
    • 5.7.4. Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market
      • 5.7.4.1. Novo Nordisk: Has filed for Approval for N9-GP and NovoEight is Doing Well
    • 5.7.5. Bayer: Markets Kogenate, Kogenate FS, and has Received FDA Approval for Kovaltry
    • 5.7.6. Limited Opportunities for Biosimilar Challenge
    • 5.7.7. Plasma and Recombinant Coagulating Factors Submarket Forecast 2018-2028
  • 5.8. Interferons
    • 5.8.1. Interferons: Key Antiviral and MS Therapies Since the 1990s
    • 5.8.2. Interferons for Treating Hepatitis: Its Influence is Decreasing
    • 5.8.3. Competition from Oral Protease and Polymerase Inhibitors
      • 5.8.3.1. Oral Therapies are Expensive
    • 5.8.4. Avonex: The Leading Interferon Therapy
      • 5.8.4.1. Avonex Revenue Forecast 2018-2028
    • 5.8.5. Rebif: Merck Attempting to Differentiate Rebif from Other Interferon Therapies
      • 5.8.5.1. Rebif Revenue Forecast 2018-2028
    • 5.8.6. Betaseron
    • 5.8.7. Plegridy: New Therapy with High Potential
    • 5.8.8. Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations
    • 5.8.9. Interferon Submarket Forecast 2018-2028
  • 5.9. Enzyme Replacement and Other Protein Therapies Submarket
    • 5.9.1. Cerezyme: Genzyme's Leading Enzyme Replacement Therapy
    • 5.9.2. Myozyme and Lumizyme
    • 5.9.3. Fabrazyme and Aldurazyme
    • 5.9.4. Botulinum Toxin Brands Include Botox, Dysport and Xeomin
    • 5.9.5. Other Protein Therapeutics Pipeline
      • 5.9.5.1. Anthera Buys Sollpura from Eli Lilly, Phase 3 Results Expected Q4 2016
      • 5.9.5.2. Multikine (CEL-SCI)
      • 5.9.5.3. Vonapantiase (Proteon Therapeutics)
    • 5.9.6. Enzyme Replacement and Other Protein Therapeutics Submarket Forecast 2018-2028

6. Monoclonal Antibodies Submarket 2018-2028

  • 6.1. Monoclonal Antibodies Submarket: Scientific and Historical Background
    • 6.1.1. Natural Antibodies: Key to the Immune System
    • 6.1.2. From Serum Therapy to Monoclonal Antibodies
    • 6.1.3. Humanising the mAb
    • 6.1.4. MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases-Great Potential for the Future
    • 6.1.5. MAbs for All? Technologies Come Off Patent
  • 6.2. Autoimmune mAbs
    • 6.2.1. Past Approvals
    • 6.2.2. Humira-The World's Best-Selling Prescription Drug
      • 6.2.2.1. AbbVie Plans to Drive Growth Through New Indications
      • 6.2.2.2. Positive Opinion from CHMP for Treatment of Non-Infectious Uveitis
      • 6.2.2.3. Recently Approved for Hidradenitis Suppurativa in the US, Europe, and Japan
      • 6.2.2.4. Biosimilar Adalimumab: Patents Protect Humira in Developed Markets for Now
      • 6.2.2.5. Humira Revenue Forecast 2018-2028
    • 6.2.3. Remicade: Second Only to Humira
      • 6.2.3.1. Has Defended Revenues Well but Now Has to Deal with Biosimilar Competition
      • 6.2.3.2. Patent Dance in US
      • 6.2.3.3. Biosimilar Infliximab: Multiple Launches
      • 6.2.3.4. Remicade Revenue Forecast 2018-2028
    • 6.2.4. Stelara: Blockbuster Status Well Established
      • 6.2.4.1. Stelara Revenues 2015-2017
      • 6.2.4.2. Orphan Drug Designation for paediatric Crohn's Disease
    • 6.2.5. Tysabri: Blockbuster Drug's High Efficacy Offsets its Risks
      • 6.2.5.1. Tysabri Revenue Forecast 2018-2028
    • 6.2.6. Xolair: New Indication, and Revenue Breakdown
    • 6.2.7. Actemra/RoActemra: Strong Growth in All Regions
    • 6.2.8. Cimzia: Blockbuster Which has been Used by Over 90,000 Patients
    • 6.2.9. Autoimmune mAbs Pipeline: RA is the Main Target
      • 6.2.9.1. Sarilumab (REGN88/SAR153191) by Regeneron and Sanofi: BLA Accepted for Review and Decision Expected by November 2016
      • 6.2.9.2. Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World
      • 6.2.9.3. Clazakizumab: Developed by Alder Biopharmaceuticals and BMS but now Licensed to Vitaeris
      • 6.2.9.4. Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results
      • 6.2.9.5. Mavrilimumab by AstraZeneca: Approaching Phase 3
      • 6.2.9.6. Zinbryta (daclizumab high-yield process) by Biogen and AbbVie: Positive Opinion from CHMP
      • 6.2.9.7. Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results
      • 6.2.9.8. Sifalimumab (MEDI-545) by AstraZeneca: Hasn't Made the Cut for Phase 3
      • 6.2.9.9. Anifrolumab by AstraZeneca
  • 6.3. Oncology mAbs
    • 6.3.1. Past Approvals
    • 6.3.2. Rising Incidence of Cancer Will Drive Demand
    • 6.3.3. Rituxan: The World's Leading Anti-Cancer mAb
    • 6.3.4. Biosimilar Rituximab: Two Candidates Await Approval in Europe
    • 6.3.5. Gazyva: Roche's Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition
      • 6.3.5.1. Approval for Follicular Lymphoma and Being Investigated for Other Indications
    • 6.3.6. Avastin: Growing under CER, Through New Indications
      • 6.3.6.1. Controversy over Off-Label Avastin use: Roche is Backed up by Incidents in India, and Opinion of EFPIA
      • 6.3.6.2. Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche, Although Various Biosimilars in Development
    • 6.3.7. Herceptin: Breast Cancer Blockbuster
      • 6.3.7.1. Pricing Challenges in Emerging Markets, and 2016 Revenues
      • 6.3.7.2. Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
      • 6.3.7.3. Herceptin Revenue Forecast 2018-2028
      • 6.3.7.4. Biosimilar Trastuzumab
    • 6.3.8. Kadcyla
      • 6.3.8.1. Mixed Results from Different Clinical Trials
      • 6.3.8.2. Kadcyla Sales Forecast 2018-2028
    • 6.3.9. Perjeta
      • 6.3.9.1. Positive Results from Different Clinical Trials
      • 6.3.9.2. Perjeta Revenue Forecast 2018-2028
    • 6.3.10. Yervoy: Bristol-Myers Squibb's Leading Anti-Cancer mAb, KeepsHigh Revenues, but with Decline over 2015
    • 6.3.11. Opdivo: Big Potential for Bristol-Myer Squibb's PD-1 Inhibitor
      • 6.3.11.1. Good News and Bad News for NSCLC from CheckMate Trials
      • 6.3.11.2. Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014
    • 6.3.12. Oncology mAbs: New Approvals and Pipeline
      • 6.3.12.1. Empliciti (Elotuzumab) by Bristol-Myers Squibb and AbbVie): Recently Approved
      • 6.3.12.2. Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb
      • 6.3.12.3. Unituxin (United Therapeutics) Receives FDA Approval March 2015
      • 6.3.12.4. SAR3419(coltuximab ravtansine) (anti-CD19, Sanofi)
  • 6.4. Monoclonal Antibodies Submarket Forecast 2018-2028

7. Fusion Proteins Submarket 2018-2028

  • 7.1. Scientific and Historical Background
  • 7.2. Differentiating Fusion Proteins
  • 7.3. Enbrel: The First FP to be Approved, in 1998
    • 7.3.1. Gradually Approved for Additional Indications
    • 7.3.2. Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
    • 7.3.3. Multiple Biosimilars Available in Emerging Markets
    • 7.3.4. Enbrel Revenue Forecast 2018-2028
  • 7.4. Eylea: Blockbuster FP Treatment for Wet AMD
    • 7.4.1. Eylea Revenue Forecast 2018-2028
  • 7.5. Orencia: Grows Blockbuster Revenues for Second Year in a Row
  • 7.6. Nplate: Generates Half a Billion in Revenues for Amgen
  • 7.7. Eloctate: Approved June 2014, Fulfils Unmet Need in the Haemophilia Community
  • 7.8. Nulojix: Bristol-Myers Squibb's Therapy for Preventing Organ Rejection
  • 7.9. Arcalyst by Regeneron Pharmaceuticals: For Very Rare Conditions
  • 7.10. Fusion Proteins Pipeline
    • 7.10.1. Trebananib (Amgen)
    • 7.10.2. Sotatercept by Acceleron Pharma and Celgene Corporation-Currently Undergoing Eight Clinical Trials
    • 7.10.3. Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development
  • 7.11. Fusion Protein Submarket Forecast to 2018-2028

8. Regenerative Medicines Submarket 2018-2028

  • 8.1. Regenerative Medicines Market Breakdown
  • 8.2. Regenerative Medicines Submarket Forecast, 2018-2028
  • 8.3. Stem Cell Therapies Submarket, 2018-2028
    • 8.3.1. Stem Cells: Scientific Breakdown
    • 8.3.2. Stem Cell Therapies Submarket Breakdown
    • 8.3.3. Haematopoietic Stem Cell Transplantation: Over 95,000 Carried out in 2016
      • 8.3.3.1. From Procedures to Products: Cord Blood Stem Cell Approvals
    • 8.3.4. Osteocel Plus: The Leading Stem Cell Orthobiologic
      • 8.3.4.1. Osteocel Plus Revenue Forecast 2018-2028
    • 8.3.5. Trinity Evolution and Trinity Elite
      • 8.3.5.1. Trinity Evolution and Trinity Elite Revenue Forecast to 2028
    • 8.3.6. MSC-100-IV (Previously Known as Prochymal): World's First Approved Stem Cell Drug Outside of South Korea
      • 8.3.6.1. An Important Role to Play in the Future of HSCT, and also Wins Approval in Japan through Partner
    • 8.3.7. CARTISTEM (MEDIPOST): The World's First Allogeneic Stem Cell Drug
    • 8.3.8. Hearticellgram-AMI (PharmaCell B.V.): One of the First Approved Cardiovascular Stem Cell Treatments in the World
    • 8.3.9. Stem Cell Therapies Pipeline
      • 8.3.9.1. Cx601 by TiGenix: Marketing Authorisation Application has been Submitted to EMA
      • 8.3.9.2. CardiAMP (BioCardia) for Heart Failure: Undergoing Phase 3 Trial and has Received Grant from MSCRF
      • 8.3.9.3. NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS in Phase 2 and Due to end Soon
      • 8.3.9.4. Agenmestencel-T (Apceth): Phase 1/2 Due to end Soon
    • 8.3.10. Stem Cell Therapies Submarket Forecast 2018-2028
  • 8.4. Tissue Engineering Therapies Submarket 2018-2028
    • 8.4.1. Tissue Engineering-In Vitro Manipulation for Therapeutic Purposes
    • 8.4.2. Current Status of the Market
    • 8.4.3. Apligraf: The Leading Product
      • 8.4.3.1. Apligraf Revenue Forecast 2018-2028
    • 8.4.4. Dermagraft: Organogenesis Further Strengthens Position Through this 2014 Acquisition
      • 8.4.4.1. Dermagraft Revenue Forecast 2018-2028
    • 8.4.5. ReCell
    • 8.4.6. MySkin and CyroSkin
    • 8.4.7. Tissue Engineering Therapies Pipeline
      • 8.4.7.1. NeoCart by Histogenics: Undergoing Phase 3 Trial for Knee Cartilage Repair
      • 8.4.7.2. Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies
      • 8.4.7.3. StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results
  • 8.5. Gene Therapies Submarket 2018-2028
    • 8.5.1. Gene Therapy: Historical and Scientific Background
    • 8.5.2. Harnessing Infectivity: Viral Vectors in Gene Therapy
    • 8.5.3. Approved Gene Therapy Products
      • 8.5.3.1. Gendicine: The World's First Commercial Gene Therapy Product
      • 8.5.3.2. Oncorine: First Oncolytic Viral Therapy
      • 8.5.3.3. Neovasculgen: Russia's First Gene Therapy
      • 8.5.3.4. Neovasculgen: Drop in Revenues in 2015, but HSCI Predicts Notable Increases as Product is Added to VED List
      • 8.5.3.5. Glybera: The First Gene Therapy for Western Markets, Although Has Abandoned Hope of Receiving FDA-Approval
    • 8.5.4. IMLYGIC
      • 8.5.4.1. IMLYGIC: Clinical Trials and Development Efforts
      • 8.5.4.2. IMLYGIC: Revenue Forecast 2018-2028
    • 8.5.5. Gene Therapies Pipeline
      • 8.5.5.1. AAV2-hRPE65v2(Spark Therapeutics): Undergoing Phase 3 Trial
      • 8.5.5.2. AdV-tk/ProstAtak (Advantagene): Phase 3
      • 8.5.5.3. Collategene (beperminogene perplasmid, AMG0001)-(AnGes MG/Vical)

9. Leading National Markets for Biologics 2018-2028

  • 9.1. Regional Forecasts for the Global Biologics Market to 2028
  • 9.2. US Biologics Market 2018-2028
    • 9.2.1. The Major National Market
    • 9.2.2. Value-Based Pricing in the US
    • 9.2.3. Regulation of Biologics in the US
    • 9.2.4. US Biosimilars Market
      • 9.2.4.1. FDA Finalises Biosimilar Guidelines and Biosimilar Naming
    • 9.2.5. US Biologics Market Forecast 2018-2028
  • 9.3. EU5 Biologics Market 2018-2028
    • 9.3.1. Current Composition and Future Outlook
    • 9.3.2. European Biosimilar Market
      • 9.3.2.1. History of EMA Guidelines and Updates
    • 9.3.3. EU5 Market Forecast by Nation 2018-2028
  • 9.4. Japanese Biologics Market 2018-2028
    • 9.4.1. Current Status of the Japanese Biologics Market
    • 9.4.2. Japanese Biosimilar Market
    • 9.4.3. Japanese Biologics Market Forecast 2018-2028
  • 9.5. BRIC National Biologic Markets 2018-2028
    • 9.5.1. BRIC Markets Overview
    • 9.5.2. BRIC Biologic Market Forecast 2018-2028
      • 9.5.2.1. Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market
      • 9.5.2.2. Future Outlook
      • 9.5.2.3. BRIC Nation Market Shares in the Global Biologics Market Will Nearly Double During the Forecast Period
    • 9.5.3. Brazil: Disproportionately High Government Spending on Biologics
      • 9.5.3.1. Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development
    • 9.5.4. Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development
    • 9.5.5. India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving
      • 9.5.5.1. CDSCO Guidelines Released in 2012
    • 9.5.6. China: Expected to be the Largest BRIC Market for Biologics by 2020
      • 9.5.6.1. The Largest National Biosimilar Market in the World

10. Qualitative Analysis of the Biologics Market and Industry

  • 10.1. SWOT Analysis of the Global Biologics Market and Industry
    • 10.1.1. Strengths
    • 10.1.2. Opportunities
    • 10.1.3. Weaknesses
    • 10.1.4. Threats
  • 10.2. STEP Analysis of the Global Biologics Market and Industry
    • 10.2.1. Social Factors
    • 10.2.2. Technological Developments
    • 10.2.3. Economic Pressures
    • 10.2.4. Political Issues

11. Company Profiles

  • 11.1. AbbVie Inc.: Profile
    • 11.1.1. AbbVie Inc.: Company Overview
  • 11.2. Amgen: Profile
    • 11.2.1. Amgen: Company Overview
  • 11.3. AstraZeneca PLC: Profile
    • 11.3.1. AstraZeneca PLC: Company Profile
  • 11.4. Bayer AG: Profile
    • 11.4.1. Bayer AG: Profile
  • 11.5. Eli Lilly: Profile
    • 11.5.1. Eli Lilly: Company Overview
  • 11.6. F. Hoffmann-La Roche Ltd.: Profile
    • 11.6.1. F. Hoffmann-La Roche Ltd.: Company Overview
  • 11.7. GlaxoSmithKline Plc.: Profile
    • 11.7.1. GlaxoSmithKline Plc.: Company Overview
  • 11.8. Johnson & Johnson Services, Inc.: Profile
    • 11.8.1. Johnson & Johnson Services, Inc.: Company Overview
  • 11.9. Merck & Co., Inc.: Profile
    • 11.9.1. Merck & Co., Inc.: Company Overview
  • 11.10. Novartis AG: Profile
    • 11.10.1. Novartis AG: Profile
  • 11.11. Pfizer Inc.: Profile
    • 11.11.1. Pfizer Inc.: Company Overview
  • 11.12. Sanofi S.A.: Profile
    • 11.12.1. Sanofi S.A: Company Overview

12. Conclusions

  • 12.1. Biologics Market to Achieve Steady Growth Throughout the Forecast Period
  • 12.2. Changes in Market Composition: mAbs to Become Leading Submarket
  • 12.3. The Emergence of Biosimilars
  • 12.4. Challenges for the Market
  • Appendices
  • Visiongain Report Sales Order Form
  • Associated Visiongain Reports
  • About Visiongain
  • Visiongain report evaluation form
Back to Top